Guggenheim analyst Subbu Nambi raised the firm’s price target on Personalis (PSNL) to $12 from $6 and keeps a Buy rating on the shares after the company announced Medicare coverage for NeXT Personal in breast cancer. This first covered indication keeps Personalis on track for their goal of two indications by year end, notes the analyst, who views this as “a major win for the story” that derisks the clinical revenue outlook for 2025.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSNL:
- Personalis price target raised to $13 from $10 at H.C. Wainwright
- Midday Fly By: Insurers slip as Senate spending bill lacks ACA extension
- Personalis Secures Medicare Coverage for NeXT Personal MRD Test, Positioning for Growth in Underpenetrated $20 Billion Market
- Personalis Gains Medicare Coverage for Cancer Test
- Personalis announces Medicare coverage of NeXT Personal test